Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
Authors
Keywords
Epidermal growth factor receptor, Mammalian target of rapamycin, Glioblastoma, Nimotuzumab, Biomarker, Targeted therapy
Journal
Acta Neuropathologica Communications
Volume 6, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-21
DOI
10.1186/s40478-018-0583-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- mTOR inhibition in glioblastoma: requiem for a dream?
- (2018) Sam Babak et al. NEURO-ONCOLOGY
- Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
- (2018) Jianfeng Huang et al. Drug Design Development and Therapy
- Immune microenvironment of gliomas
- (2017) Anna Gieryng et al. LABORATORY INVESTIGATION
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
- (2017) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma
- (2017) Jacob J Mandel et al. NEURO-ONCOLOGY
- Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
- (2017) Tobias Kessler et al. NEURO-ONCOLOGY
- Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype
- (2017) M. D. Sørensen et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
- (2016) W. Wick et al. CLINICAL CANCER RESEARCH
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
- (2015) Dawn Q Chong et al. BMC CANCER
- A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
- (2015) Manfred Westphal et al. EUROPEAN JOURNAL OF CANCER
- Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors
- (2015) Patrick N. Harter et al. PLoS One
- Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody
- (2015) Wenjie Luo et al. Scientific Reports
- MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas
- (2014) Pia S. Zeiner et al. BRAIN PATHOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
- (2014) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Regulation of mTORC1 by amino acids
- (2014) Liron Bar-Peled et al. TRENDS IN CELL BIOLOGY
- Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
- (2013) Michael Weller et al. INTERNATIONAL JOURNAL OF CANCER
- HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
- (2013) Gregg L. Semenza JOURNAL OF CLINICAL INVESTIGATION
- Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair
- (2013) Yuan-yuan Qu et al. PLoS One
- Tumor-Associated Macrophages in Glioma: Friend or Foe?
- (2013) Benjamin C. Kennedy et al. Journal of Oncology
- Nimotuzumab treatment of malignant gliomas
- (2012) Udo Bode et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
- (2012) Christian C. Dibble et al. MOLECULAR CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience
- (2011) Johannes E. Wolff et al. JOURNAL OF NEURO-ONCOLOGY
- Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
- (2011) Stephanie E Combs et al. Radiation Oncology
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- Nimotuzumab for pediatric diffuse intrinsic pontine gliomas
- (2010) Maura Massimino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives
- (2010) Michael W. Ronellenfitsch et al. Targeted Oncology
- Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
- (2009) Michael W. Ronellenfitsch et al. BRAIN
- Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation
- (2009) A. Talavera et al. CANCER RESEARCH
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
- (2009) Sean M. McBride et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
- (2008) Monika E. Hegi et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More